Fortive Corporation Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Fortive Corporation Common Stock trades at $57.21 (market cap $17.54B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Fortive Corporation Common Stock is the larger of the two by market cap, and Fortive Corporation Common Stock pays a 0.48% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortive Corporation Common Stock for 6 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| FTV | PCVX | |
|---|---|---|
Market Cap | $17.54B | $10.51B |
Volume | 1,898,662 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $64.09 | $73.82 |
52-Week Low | $48.49 | $40.32 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $20.67B | $9.14B |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
Fortive Corporation (FTV) trades at $58.07, up 1.22% today, with a neutral technical signal and a consensus analyst price target of $63.33. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue growth is modest, but profitability remains solid with a 12.38% net income margin. Recent news highlights product launches and a dividend increase, while institutional activity includes mixed buying and selling.
The outlook is cautiously positive, supported by raised 2026 guidance and core growth acceleration. Key risks include competitive pressures and macroeconomic headwinds. Analyst sentiment is mixed, with 36.67% buy ratings, but the stock offers potential upside to the consensus target if execution continues to improve.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Fortive provides industrial and healthcare technology solutions. Its products and software support measurement, maintenance, worker safety, instrument sterilization, and clinical workflows.
Read more on FTV →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →